scientif
advanc
led
largescal
product
widespread
distribut
vaccin
antivir
drug
virus
still
remain
major
caus
human
diseas
today
everincreas
report
viral
resist
emerg
reemerg
viral
epidem
pressur
health
scientif
commun
constantli
find
novel
molecul
antivir
potenti
search
involv
numer
differ
approach
use
antimicrobi
peptid
present
interest
altern
even
though
number
antimicrobi
peptid
antivir
activ
still
low
alreadi
show
immens
potenti
becom
pharmaceut
avail
antivir
drug
peptid
origin
natur
sourc
isol
mammal
anim
venom
artifici
sourc
bioinformat
tool
use
review
aim
shed
light
antimicrobi
peptid
antivir
activ
human
virus
updat
data
alreadi
wellknown
peptid
still
undergo
studi
emphas
promis
one
may
becom
medicin
clinic
use
publish
note
springer
natur
remain
neutral
regard
jurisdict
claim
publish
map
institut
affili
even
though
viral
infect
report
sinc
ancient
time
nineteenth
centuri
scientist
abl
isol
filter
particl
later
call
virus
sinc
major
breakthrough
regard
control
viral
reproduct
infect
product
vaccin
led
remark
advanc
humanviru
interact
smallpox
erad
control
measl
poliomyel
transmiss
nevertheless
virus
still
remain
one
main
caus
human
diseas
mainli
discoveri
develop
new
vaccin
usual
challeng
time
consum
reason
commonli
util
altern
avail
viral
control
treatment
antivir
drug
overal
view
common
mechan
action
antivir
drug
virustarget
antivir
hosttarget
antivir
virustarget
antivir
focu
inhibit
import
transcript
replic
enzym
proteas
polymeras
direct
inactiv
viral
structur
protein
contrast
hosttarget
antivir
focu
inhibit
cyclophilin
known
import
cellular
factor
hijack
virus
replic
cycl
use
immunomodul
interferon
gamma
globulin
firstgener
antivir
molecul
describ
earli
seriou
side
effect
human
due
poor
specif
exampl
vidarabin
adenosin
analog
use
replic
inhibitor
affect
viral
dna
polymeras
also
eukaryot
analog
advanc
research
area
led
descript
better
molecul
acyclovir
first
nucleosid
analog
antivir
drug
consid
success
treatment
herp
simplex
viru
hsv
varicella
zoster
viru
vzv
infect
specificityit
requir
phosphoryl
step
mediat
viral
proteinthi
molecul
caus
lower
toxic
host
compar
previous
use
treatment
unfortun
low
efficaci
antivir
treatment
still
evidenc
everincreas
report
viral
resist
concomit
viral
infect
emerg
reemerg
viral
epidem
rel
short
period
time
observ
ebola
zika
viru
zikv
first
year
present
decad
therefor
demand
product
new
antivir
drug
higher
ever
increas
prefer
molecul
capabl
present
broadspectrum
activ
search
new
molecul
involv
differ
approach
bioinformaticsassist
predict
base
molecul
interact
import
viral
structur
enzym
isol
new
compound
obtain
natur
sourc
use
techniqu
mani
new
molecul
describ
far
recent
descript
antimicrobi
peptid
gain
attent
recent
evid
highlight
function
antivir
proteinac
compound
defens
barrier
demonstr
antimicrobi
peptid
may
also
present
activ
broad
rang
virus
thu
call
antivir
peptid
avp
molecul
also
obtain
util
bioinformat
tool
call
design
artifici
avp
deriv
bait
studi
artifici
peptid
test
interact
specif
target
surfac
glycoprotein
import
viral
enzym
obtain
silico
use
specif
softwar
design
predict
peptid
case
mani
set
taken
consider
topolog
amino
acid
composit
charg
mani
chemic
structur
characterist
may
influenc
antivir
activ
peptid
studi
avp
focu
numer
research
project
recent
year
structur
mechan
action
molecul
previous
review
even
compil
onlin
databas
antivir
peptid
databas
avpdbhttp
crddosddnetserv
rsavpdb
entri
experiment
test
peptid
regard
mechan
action
fig
mostli
call
virucid
act
directli
inhibit
viral
particl
compet
protein
link
site
host
cell
membran
interf
interact
consequ
adsorpt
howev
may
also
act
stage
viral
cycl
caus
exampl
suppress
viral
gene
express
due
increas
number
studi
demonstr
antivir
activ
peptid
press
need
new
antivir
drug
articl
aim
compil
relev
inform
promis
antivir
peptid
may
becom
effect
drug
still
undergo
studi
andor
clinic
trial
peptid
studi
least
decad
broad
spectrum
biolog
activ
describ
far
case
given
peptid
show
one
activ
therefor
call
promiscu
peptid
overal
biochem
featur
avp
cation
amphipath
characterist
posit
net
charg
essenti
peptid
work
antimicrobi
moreov
evid
great
physicochem
differ
amp
avp
wang
et
al
show
largescal
analysi
correl
antimicrobi
activ
amphipath
charg
howev
data
show
hydrophob
seem
import
properti
peptid
activ
envelop
virus
among
advantag
natur
avp
one
cite
possibl
high
specif
effect
low
toxic
peptidas
biodegrad
limit
accumul
tissu
low
molecular
weight
otherwis
short
halflif
immunogen
potenti
high
cost
product
low
oral
absorpt
limit
use
compound
antivir
follow
section
provid
descript
natur
deriv
avp
mode
action
potenti
pharmaceut
molecul
moreov
exampl
antivir
peptid
structur
align
shown
fig
respect
plant
util
divers
array
small
cation
cysteinerich
protein
toxic
weapon
fend
pest
pathogen
attack
peptid
well
known
capac
obstruct
wide
array
viru
infect
caus
econom
import
diseas
crop
recent
year
plantderiv
defens
peptid
becom
focu
numer
studi
potenti
use
novel
molecul
treatment
human
viral
diseas
cyclotid
larg
famili
plantderiv
peptid
character
cyclic
backbon
three
conserv
disulfid
bond
form
knotlik
rigid
structur
broad
rang
biolog
role
includ
antimicrobi
anthelminth
nematocid
insecticid
activ
cyclotid
differ
plant
speci
significantli
investig
abil
hinder
growth
virus
involv
human
diseas
human
immunodefici
viru
hiv
influenza
dengu
denv
one
exampl
kalata
wellstudi
cyclotid
found
leav
african
plant
oldenlandia
affini
kalata
show
strong
antihiv
activ
capabl
destroy
viral
particl
prior
cell
entri
well
inhibit
fusion
viru
host
membran
antivir
activ
kalata
plant
cyclotid
seem
reli
mechan
util
peptid
hinder
growth
microbi
pathogen
abil
bind
disrupt
pathogen
cell
membran
due
cation
amphipath
natur
well
small
size
cyclotid
easili
bind
aggreg
within
lipid
bacteri
fungal
membran
interact
disrupt
membran
organ
lead
format
pore
caus
leakag
intern
cell
compon
consequ
cell
death
envelop
virus
hiv
use
host
cell
membran
form
outer
wrap
compos
specif
lipid
microdomain
necessari
viru
replic
cycl
thu
cyclotid
also
capabl
disturb
viru
lipid
envelop
lead
inhibit
viral
fusion
target
cell
destruct
viral
particl
pharmaceut
potenti
cyclotid
highlight
aforement
antivir
properti
also
capac
toler
high
number
substitut
amino
acid
backbon
maintain
biolog
activ
reason
cyclotid
constantli
use
scaffold
novel
drug
design
exampl
amino
acid
modif
perform
kalata
allow
design
novel
kalata
peptid
present
activ
dengu
viru
plant
defenserel
peptid
may
curtail
human
viru
infect
interact
interfer
protein
fundament
viral
replic
cycl
exampl
phaseococcin
sesquin
two
antimicrobi
peptid
isol
respect
seed
runner
bean
phaseolu
coccineu
ground
bean
vigna
sesquipedali
capabl
inhibit
revers
transcriptas
activ
hiv
viru
thu
hinder
viral
replic
virucid
activ
observ
kda
antivir
peptid
isol
sorghum
bicolor
seed
may
explain
capac
peptid
bind
mask
essenti
viral
envelop
protein
fact
modul
activ
enzym
involv
viral
infect
replic
appear
one
promin
mechan
util
plant
peptid
inhibit
viral
prolifer
arthropod
rich
sourc
compound
divers
activ
includ
sever
antimicrobi
peptid
surprisingli
recent
mani
arthropodderiv
molecul
describ
antivir
activ
situat
appear
chang
numer
novel
molecul
antivir
properti
isol
organ
exampl
cecropin
acid
peptid
deriv
moth
hyalophora
cecropia
show
inhibitori
activ
hiv
mechan
seem
suppress
viral
gene
express
anoth
assay
show
cecropin
also
inhibitori
activ
herp
simplex
viru
hsv
junin
viru
jv
replic
inhibit
jv
reach
bee
api
mellifera
venom
also
interest
sourc
avp
one
exampl
bee
venomderiv
avp
melittin
test
assay
infect
lymphoma
cell
interestingli
cell
cultur
treat
melittin
show
almost
total
absenc
viral
particl
peptid
also
test
jv
show
high
inhibit
viral
replic
test
virus
rel
low
concentr
previou
studi
carri
waching
et
al
action
antivir
melittin
alreadi
proven
believ
peptid
activ
envelop
virus
reli
viral
envelop
lysi
recent
hood
et
al
shown
nanoparticl
incorpor
melittin
abl
prevent
vitro
hiv
infect
toxic
vagin
epithelium
cell
use
assay
arthropod
venom
recur
theme
studi
search
new
avp
recent
research
use
mastoparan
peptid
deriv
wasp
venom
vespula
lewisii
develop
new
peptid
mastoparan
show
broad
antivir
activ
envelop
virus
ten
virus
test
avp
reach
replic
inhibit
eight
preincub
vivo
assay
perform
indian
vesicular
stomat
viru
vsv
peptid
made
viru
noninfecti
unabl
replic
vivo
transmiss
electron
microscopi
tem
assay
observ
vsv
virion
treat
mastoparan
signific
envelop
disrupt
appear
separ
capsid
lactarcin
deriv
venom
lachesana
tarabaev
spider
central
asia
demonstr
inhibitori
activ
proteinprotein
dock
analysi
suggest
lactarcin
could
bind
viral
proteas
near
activ
site
verifi
elisa
western
blot
assay
antivir
activ
confirm
cell
cultur
assay
reach
viral
inhibit
viral
proteas
seem
vital
viral
replic
block
lead
consequ
dengu
inhibit
venom
scorpion
anoth
rich
sourc
arthropod
venomderiv
avp
venom
secret
asian
forest
scorpion
heterometru
petersii
contain
peptid
capabl
inhibit
replic
hepat
c
viru
hcv
prevent
infect
instal
assay
use
show
avp
capabl
block
viru
attach
target
cell
inactiv
viral
particl
alreadi
attach
yet
penetr
artifici
design
peptid
deriv
chines
swim
scorpion
lycha
mucronatu
present
outstand
inhibitori
activ
measl
viru
influenza
sever
acut
respiratori
syndrom
coronaviru
sarscov
differ
origin
molecul
exchang
glycin
prolin
residu
arginin
lysin
give
variant
greater
posit
net
charg
peptid
hydrophil
side
improv
interact
viru
envelop
reason
author
suggest
virucid
mechan
action
studi
show
activ
hepat
b
viru
hbv
vitro
vivo
inhibit
viral
replic
activ
map
kinas
rout
decreas
express
import
factor
hbv
replic
chen
et
al
synthes
acid
residu
peptid
name
improv
peptid
deriv
mesobuthu
martensii
scorpion
venom
show
low
cytotox
antivir
activ
variant
subtyp
b
reach
almost
viral
inhibit
direct
inactiv
viral
particl
present
promis
antivir
drug
candid
recent
zeng
et
al
screen
venom
peptid
deriv
euscorpiop
validu
scorpion
identifi
antivir
peptid
studi
author
tri
improv
peptid
cellular
uptak
intracellular
distribut
introduc
histidin
residu
would
enhanc
helic
amphiphil
result
show
modifi
peptid
lowest
cytotox
highest
antivir
activ
enhanc
cellular
uptak
better
cellular
distribut
final
peptid
alloferon
deriv
hemolymph
blowfli
calliphora
vicina
show
antitumor
activ
well
antivir
activ
two
influenza
variant
peptid
also
test
regard
immunomodulatori
activ
demonstr
alloferon
capac
influenc
activ
natur
killer
cell
host
releas
interferon
import
cytokin
involv
immun
respons
process
recent
studi
kuczer
et
al
test
alloferon
analog
coxsackieviru
three
differ
type
cell
cultur
result
show
inhibitori
activ
origin
peptid
analog
consider
diminish
viral
replic
h
contact
vitro
assay
compound
analog
show
best
inhibitori
activ
analog
modif
ntermin
portion
alloferon
promis
candid
design
new
avp
due
optim
antivir
activ
absenc
toxic
toward
mammalian
cell
howev
mechan
action
remain
fulli
elucid
frog
skin
consid
abund
sourc
antimicrobi
peptid
howev
still
mani
frogderiv
peptid
antivir
activ
describ
literatur
produc
dermal
gland
deploy
event
stress
gener
present
cation
amphipath
secondari
structur
amino
acid
exampl
magainin
deriv
frog
xenopu
laevi
amino
acid
residu
avp
test
show
effici
inhibit
virus
previous
magainin
variant
also
test
one
present
lysinerich
region
mani
lysin
residu
structur
show
best
result
inhibit
viru
author
suggest
cation
charg
associ
amphipath
structur
may
enabl
peptid
interact
viral
envelop
anion
phospholipid
consequ
disrupt
structur
unknown
mechan
exert
virucid
activ
dean
et
al
test
alaninesubstitut
amid
along
three
peptid
vaccinia
viru
evalu
virucid
activ
variant
show
satisfactori
activ
viru
attack
envelop
anoth
peptid
capabl
target
viral
envelop
temporin
b
deriv
frog
speci
rana
temporaria
avp
show
high
antivir
activ
vitro
plaqu
assay
author
show
temporin
b
inhibit
dosedepend
manner
reach
interf
celltocel
spread
viru
suggest
peptid
may
target
cellular
mechan
use
viru
virucid
action
reach
inhibit
suggest
peptid
act
viral
particl
verifi
hypothesi
tem
studi
conduct
show
virion
treat
temporin
b
loss
envelop
integr
dermaseptin
larg
famili
antimicrobi
peptid
produc
frog
phyllomedusa
genu
antivir
activ
peptid
alreadi
describ
viral
envelop
appear
preferenti
target
dermaseptin
deriv
recent
deriv
dermaseptin
deriv
test
rabi
viru
vitro
vivo
assay
deriv
methionin
exchang
lysin
deriv
show
strongest
antivir
activ
reach
inhibit
cell
cultur
assay
moreov
test
mice
show
protect
effect
increas
surviv
rate
treat
mice
relat
control
mice
thu
author
suggest
specif
exchang
dermaseptin
therefor
creat
decreas
cytotox
substitut
hydrophob
posit
net
charg
amino
acid
given
result
dermaseptin
virucid
mechan
action
also
affect
earli
stage
intracellular
infect
rabi
viru
moreov
avp
deriv
anuran
hypsiboa
semilineatu
skin
show
remark
antivir
activ
specif
pretreat
inhibit
viral
adsorpt
assay
percentag
inhibit
reach
almost
virus
antivir
activ
observ
stage
viral
cycl
led
author
infer
act
upon
earli
stage
infect
corrobor
result
qpcr
assay
atom
forc
microscopi
analysi
conduct
show
number
viral
genom
virus
reduc
also
viral
envelop
appear
disturb
invagin
contact
peptid
last
exampl
virucid
frog
peptid
urumin
avp
deriv
indian
frog
hydrophylax
bahuvistara
urumin
show
strong
inhibitori
activ
influenza
viru
vitro
vivo
test
vitro
assay
urumin
show
inhibit
strain
unaffect
fact
led
author
suggest
urumin
abl
interact
hemagglutinin
tem
assay
therefor
conduct
show
influenza
virion
destroy
vivo
assay
balbc
mice
treat
urumin
administ
intranas
inocul
influenza
result
show
urumintr
mice
less
morbid
nontreat
anoth
rich
sourc
avp
found
among
aquat
live
be
studi
possibl
clavanin
class
peptid
deriv
tunic
call
styela
clava
studi
perform
yasin
et
al
clavanin
ak
show
inhibit
percentag
inhibit
clavanin
test
rotaviru
adenoviru
nonenvelop
vitro
possibl
verifi
viral
inactiv
inocul
cell
cultur
pretreat
step
peptid
inocul
cell
culturecal
simultan
testclavanin
show
better
inhibit
rotaviru
pretreat
reach
inhibit
howev
peptid
best
activ
adenoviru
happen
simultan
test
reach
inhibit
clavanin
b
also
show
inhibitori
activ
hiv
addit
four
cyclic
depsipeptid
mirabamid
e
f
g
h
isol
marin
spong
stelletta
clavosa
chemic
properti
structur
defin
test
hiv
strain
show
strong
inhibitori
activ
vitro
assay
peptid
mirabamid
h
show
best
antivir
activ
ic
valu
around
follow
f
g
mirabamid
e
recent
studi
carri
migliolo
et
al
peptid
pamap
deriv
polar
fish
call
pleunorectu
americanu
structur
physicochem
antimicrobi
properti
extens
studi
show
antibacteri
antifung
activ
also
antitumor
final
antivir
activ
later
assay
found
pamap
virucid
mechan
action
mean
peptid
possibl
interact
viral
surfac
glycoprotein
among
antimicrobi
peptid
deriv
mammal
two
main
famili
frequent
studi
antivir
properti
defensin
cathelicidin
cation
charg
amphipath
properti
defensin
predomin
sheet
stabil
three
disulfid
bond
rang
amino
acid
residu
wherea
cathelicidin
ntermin
signal
sequenc
conserv
cathelinlik
domain
variabl
ctermin
domain
need
proteolyt
cleavag
matur
rang
amino
acid
residu
defensin
produc
keratinocyt
upon
skin
lesion
classifi
three
group
also
known
human
neutrophil
peptid
hnp
hbd
produc
higher
primat
human
be
regard
antivir
activ
defensin
hnp
show
antivir
activ
hiv
among
present
best
result
anoth
studi
salvator
et
al
also
show
activ
influenza
viru
suggest
peptid
inhibit
viru
initi
stage
cycl
establish
infect
influenza
use
pkc
signal
pathway
cell
data
show
pkc
phosphoryl
decreas
infect
cell
treat
show
interf
viral
cycl
hand
mani
human
alreadi
describ
two
stand
potenti
antivir
activ
describ
product
induc
viral
presenc
organ
meyerhoffert
et
al
investig
presenc
peptid
lesion
verruca
vulgari
condylomata
acuminata
cutan
lesion
caus
differ
subtyp
hpv
result
show
increas
express
viral
infect
howev
author
unabl
ensur
express
peptid
fact
induc
hpv
infect
sinc
also
induc
proinflammatori
cytokin
suggest
studi
address
matter
moreov
also
demonstr
capabl
inhibit
vaccinia
viru
demonstr
presenc
viru
induc
product
peptid
keratinocyt
addit
anoth
studi
show
vzv
inhibit
keratinocyt
et
al
show
antivir
activ
hiv
zapata
et
al
recent
show
mrna
express
seroneg
hesn
individu
seroposit
patient
result
suggest
hbd
inhibit
viru
earli
step
cycl
also
late
revers
transcript
nuclear
import
hiv
indic
best
result
final
author
propos
peptid
could
use
retrovir
therapi
futur
furthermor
cathelicidin
demonstr
inhibitori
activ
toward
sever
envelop
virus
includ
vzv
vaccinia
viru
vv
hiv
syncyti
respiratori
viru
rsv
influenza
viru
hcv
dengu
viru
serotyp
zika
viru
recent
venezuelan
equin
enceph
viru
veev
infect
equin
human
propos
mechan
action
envelop
virus
describ
damag
envelop
protect
target
cell
infect
modul
viral
compon
necessari
replic
infect
hiv
revers
transcriptas
also
describ
moreov
show
antivir
activ
nonenvelop
viru
adenoviru
aichi
viru
rhinoviru
howev
suggest
peptid
use
differ
mechan
inhibit
nonenvelop
virus
adenoviru
strain
therefor
studi
need
elucid
matter
besid
defensin
cathelicidin
peptid
found
mammal
lactoferrin
peptid
deriv
mammal
milk
studi
past
year
possess
variou
antimicrobi
immunomodulatori
properti
lactoferrin
antivir
activ
alreadi
describ
mani
virus
cmv
adenoviru
rotaviru
polioviru
rsv
hiv
influenza
hcv
hbv
recent
bovin
lactoferrin
show
activ
dengu
chikungunya
zika
virus
three
transmit
aed
aegypti
mosquito
lactoferricin
smaller
peptid
deriv
ntermin
region
lactoferrin
also
describ
antivir
peptid
inhibitori
activ
show
variou
virus
cmv
cyclic
form
lactoferricin
abl
prevent
viral
entri
fibroblast
variant
peptid
also
test
hpv
demonstr
differ
percentag
inhibit
vitro
test
lactoferricin
test
vitro
assay
result
show
intracellular
traffick
delay
presenc
peptid
molecular
mechan
action
propos
possibl
involv
interfer
host
cell
microtubul
need
success
viral
replic
moreov
peptid
test
wellestablish
vivo
assay
femal
mice
inocul
viru
peptid
show
sign
diseas
final
wang
et
al
show
presenc
lactoferricin
reduct
integras
nuclear
distribut
mechan
use
viru
integr
genet
materi
within
cell
mediat
enzym
call
integras
addit
cyclic
cation
peptid
amino
acid
residu
deriv
swine
white
blood
cell
show
activ
dengu
viru
peptid
abl
inhibit
specif
viral
proteas
import
replic
name
interestingli
enantiom
compos
entir
amino
acid
form
show
activ
final
cyvip
deriv
human
hemofiltr
show
effici
inhibit
cmv
vitro
mechan
action
resid
peptid
interact
heparan
sulfat
receptor
host
cell
surfac
also
virus
target
receptor
use
viral
surfac
glycoprotein
adsorpt
therefor
bind
site
avail
adsorpt
would
compromis
final
sala
et
al
evalu
sever
synthet
peptid
deriv
differ
human
serum
protein
four
virus
among
peptid
call
kp
show
remark
antivir
activ
reach
inhibit
virucid
manner
vsv
anoth
envelop
viru
inhibit
rate
reach
author
suggest
kp
show
hydrophob
amino
acid
sequenc
may
interact
viral
envelop
lipid
andor
glycoprotein
nevertheless
differ
composit
organ
vsv
envelop
may
influenc
differ
result
besid
descript
natur
peptid
anoth
way
discov
new
antivir
drug
predict
ration
design
novel
molecul
basic
three
major
method
use
ration
design
templatebas
design
physicochem
de
novo
method
aim
creat
novel
peptid
andor
improv
alreadi
exist
one
templatebas
design
aim
add
select
andor
increas
activ
known
peptid
sequenc
includ
amino
acid
chang
posit
therefor
reduc
peptid
size
modif
lead
creation
novel
avp
even
inact
peptid
physicochem
design
also
use
known
sequenc
gener
analog
differ
physicochem
properti
final
de
novo
method
creat
new
peptid
use
amino
acid
pattern
frequenc
recent
new
algorithm
creat
specif
predict
antivir
peptid
call
antivpp
avail
http
githu
bcombiocodin
gantiv
pp
author
suggest
algorithm
fast
accur
intuit
tool
state
number
hydrogenbond
donor
import
featur
consid
develop
avp
predict
algorithm
method
appli
avp
design
research
usual
base
new
molecul
specif
viral
structur
surfac
glycoprotein
viral
proteas
import
enzym
brought
within
viral
particl
therefor
knowledg
viral
genom
protein
structur
replic
cycl
host
cell
target
great
import
descript
effici
inhibitor
interestingli
case
peptid
design
target
specif
viru
use
templat
design
new
peptid
differ
viru
viral
surfac
glycoprotein
often
target
essenti
entri
penetr
process
requir
conform
chang
given
proteinprotein
interact
undergo
addit
sequenc
conserv
region
use
model
new
molecul
given
ration
design
avp
tend
virusspecif
follow
section
review
list
recent
avp
separ
viru
target
dengu
viru
mosquitoborn
flaviviru
genom
encod
three
structur
protein
capsid
c
premembran
prm
envelop
e
seven
nonstructur
protein
nss
e
protein
glycosyl
import
role
viral
adsorpt
entri
amino
acid
ctermin
consist
highli
conserv
stem
region
form
two
helic
partial
insert
lipid
envelop
final
ntermin
ectodomain
form
three
domain
edi
edii
edii
peptid
mimet
e
protein
stem
region
test
wnv
show
inhibit
virus
concentr
lower
recent
assay
test
four
dengu
serotyp
show
inhibit
infect
releas
viral
genom
hole
form
envelop
moreov
vitro
assay
mammalian
epitheli
mosquito
cell
toxic
found
inhibit
neither
seen
preincub
assay
peptid
postinfect
assaysonli
coincubationprov
clearli
attack
viral
particl
directli
costin
et
al
design
variou
peptid
mimic
sequenc
edii
near
ediedii
hing
region
extend
beta
sheet
region
compris
first
connect
edi
edii
comput
work
aim
optim
structur
seven
artifici
avp
select
synthesi
vitro
challeng
result
show
peptid
abl
inhibit
viru
concentr
respect
furthermor
chosen
cryoem
assay
result
show
viral
particl
treat
peptid
lost
icosahedr
symmetri
lead
inhibit
viral
entri
recent
cui
et
al
test
hypothesi
dengu
e
protein
could
interact
integrin
host
cell
surfac
receptor
specif
assay
occurr
interact
proven
therefor
eight
peptid
synthes
base
structur
e
protein
result
show
two
peptid
design
base
ediii
region
name
abl
inhibit
interact
denv
e
protein
integrin
denv
author
also
mention
mechan
inhibit
two
peptid
occupi
bind
site
integrin
consequ
prevent
viral
entri
host
cell
glycoprotein
b
wellconserv
import
surfac
protein
present
envelop
along
surfac
glycoprotein
gcgm
involv
viru
attach
penetr
host
cell
structur
target
assay
search
hsv
entri
inhibitor
one
conduct
akkarawongsa
et
al
multipl
peptid
homolog
gb
synthes
test
result
show
molecul
synthes
best
inhibitori
activ
concentr
lower
assay
perform
infer
mechan
action
show
abl
interfer
entri
step
ec
respect
howev
could
inhibit
direct
viral
particl
higher
concentr
final
transloc
express
viral
tegument
protein
immedi
earli
protein
respect
measur
confirm
activ
earli
step
infect
show
reduct
nuclear
express
presenc
peptid
anoth
studi
peptid
synthes
base
highli
conserv
amino
acid
sequenc
gb
gh
inhibit
assay
given
establish
paramet
four
peptid
two
glycoprotein
select
virucid
antivir
vitro
assay
interestingli
peptid
deriv
gb
show
virucid
activ
virus
reach
inhibit
wherea
deriv
gh
abl
inhibit
infect
particl
higher
concentr
also
present
limit
activ
almost
observ
antivir
assay
gb
peptid
show
inhibit
virus
gh
peptid
show
better
protect
much
higher
concentr
respect
assay
led
author
suggest
may
act
postbind
step
possibl
upstream
compon
entri
machineri
may
interact
gc
least
herpesconserv
glycoprotein
conclus
improv
gh
deriv
peptid
need
diminish
concentr
necessari
achiev
satisfactori
viral
inhibit
among
virus
caus
human
diseas
none
ever
caus
concern
worldwid
hiv
million
peopl
infect
current
avail
antivir
treatment
target
four
step
viral
cycl
viral
entri
revers
transcript
integr
virion
matur
howev
sinc
differ
evolutionari
histori
share
genet
similar
antivir
capabl
inhibit
inhibit
recent
mani
studi
focus
entryfus
inhibitor
molecul
mainli
one
target
hiv
envelop
import
glycoprotein
viral
fusion
entri
host
cell
amino
acid
residu
form
cytoplasm
domain
transmembran
domain
ectodomain
ectodomain
three
import
region
fusion
peptid
region
ntermin
helic
heptad
repeat
region
nhr
ctermin
helic
heptad
repeat
region
chr
fusion
process
nhr
chr
form
sixhelix
bundl
core
moreov
hydrophob
pocket
nhr
trimer
import
stabil
thu
interest
target
small
molecul
design
briefli
two
major
class
hiv
entri
inhibitor
target
chr
target
nhr
base
nativ
chr
sequenc
peptid
gener
name
efurtivid
brand
name
fuzeon
exampl
antivir
peptid
alreadi
approv
clinic
use
hiv
patient
repres
first
gener
entri
inhibitor
basic
use
treatment
patient
show
evid
viral
replic
despit
ongo
antiretrovir
therapi
despit
efficaci
resist
occur
due
extend
exposur
poor
bioavail
largedos
requir
cross
reaction
preexist
antibodi
patient
furthermor
shown
activ
decreas
addit
cpeptidebas
molecul
sifuvirtid
show
longer
halflif
higher
potenc
lower
threshold
resist
besid
phase
iib
clinic
trial
china
show
improv
efficaci
better
rate
undetect
viral
load
recent
approv
phase
iii
clinic
trial
anoth
promis
cpeptid
design
amino
acid
profil
minim
antigen
immunogen
preserv
enhanc
antivir
activ
mother
molecul
decreas
antigen
immunogen
strategi
use
sever
studi
avoid
cross
reaction
patient
preexist
antibodi
potenti
impair
treatment
furthermor
author
test
whether
would
recogn
patient
serum
alreadi
immun
recognit
observ
thu
suggest
could
safer
drug
strategi
mention
also
use
anoth
peptid
call
npeptid
borrego
et
al
studi
ancestr
sequenc
deriv
simian
immunodefici
viru
siv
design
peptid
overlap
ntermin
pocketbind
region
heptad
repeat
core
region
vitro
assay
inhibit
infect
significantli
activ
former
latter
moreov
presenc
patient
infect
plasma
poor
reaction
peptid
patient
antibodi
seen
comparison
reaction
result
expect
sinc
region
differ
significantli
therefor
antibodi
gener
region
unlik
bind
peptid
deriv
final
author
suggest
could
use
altern
treatment
patient
assay
et
al
formul
gel
hydroxyethyl
cellulos
hec
perform
vivo
test
balbc
mice
idea
creat
microbicid
could
use
intravagin
prevent
hiv
infect
author
describ
high
stabil
bioactiv
genit
human
fluid
even
month
exposur
differ
ph
valu
temperatur
presenc
hydrogen
peroxid
importantli
bacteri
toxic
vagin
microbiota
observ
make
gel
promis
candid
develop
vagin
microbicid
gel
use
prophylaxi
women
simpli
mt
hook
structur
anoth
approach
use
improv
entri
inhibitor
peptid
hiv
treatment
form
two
residu
preced
pocketbind
domain
pbd
chr
peptid
modif
confer
extens
hydrophob
interact
pbd
thu
improv
bind
affin
antivir
activ
suggest
highli
conserv
pocket
region
siv
therefor
xiong
et
al
gener
fusion
inhibitor
peptid
pocket
site
target
comparison
peptid
use
control
like
show
increas
inhibitori
activ
siv
also
effect
subtyp
hiv
mutant
primari
isol
assay
group
led
improv
ad
fatti
acid
group
c
c
terminu
produc
result
show
could
inhibit
siv
much
lower
concentr
especi
assay
inhibit
viru
entri
lipid
conjug
strategi
improv
peptid
bind
stabil
antivir
activ
vitro
ex
vivo
assay
provid
good
candid
drug
develop
influenza
viru
present
major
threat
human
health
respons
mani
epidem
year
given
segment
singlestrand
rna
genom
influenza
virus
high
degre
genom
variat
caus
point
mutat
chang
larg
sequenc
reassort
trigger
anim
infect
differ
strain
influenza
exchang
genom
segment
thu
result
new
strain
despit
frequent
vaccin
polici
minim
viral
transmiss
event
antigen
mismatch
virus
use
vaccin
one
circul
commun
still
make
measur
ineffect
addit
two
class
antivir
drug
influenza
adamantan
neuraminidas
inhibitor
alreadi
describ
case
resist
thu
new
molecul
need
current
studi
target
one
viral
spike
call
hemagglutinin
ha
neuraminidas
na
princip
glycoprotein
involv
entri
releas
process
influenza
ha
form
two
subunit
consid
homotrimer
type
membran
glycoprotein
subunit
connect
one
disulfid
bond
form
globular
head
domain
contain
receptorbind
site
rb
ha
stem
structur
respons
intraendosom
membran
fusion
base
conserv
region
ha
influenza
sever
peptid
design
et
al
nine
peptid
design
three
deriv
ntermin
region
three
deriv
ctermin
anoth
three
deriv
test
vitro
four
differ
strain
influenza
human
swine
avian
origin
ha
subtyp
result
show
nine
peptid
abl
inhibit
four
influenza
strain
concentr
rang
furthermor
dock
analysi
subtyp
suggest
antivir
activ
could
relat
multipl
interact
avp
relev
region
ha
could
impair
conform
chang
need
membran
fusion
process
recent
strategi
design
peptid
base
broad
neutral
monoclon
antibodi
bnab
bind
conserv
ha
stem
region
koday
et
al
describ
peptid
name
whose
structur
mimic
stembind
region
bnab
ha
vitro
result
show
activ
multipl
ha
subtyp
neutral
distinct
human
avian
influenza
virus
furthermor
test
mice
preexposur
treatment
prevent
infect
also
induc
inflammatori
respons
henc
postexposur
treatment
block
interf
viral
spread
altogeth
result
suggest
peptid
could
use
prevent
infect
treat
diseas
without
exacerb
inflammatori
respons
human
coronavirus
positivesens
rna
envelop
virus
belong
coronavirida
famili
far
six
coronavirus
cov
report
infect
human
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
associ
upper
mild
respiratori
tract
infect
sarscov
merscov
caus
varieti
sever
flulik
symptom
respons
recent
epidem
respect
basic
viral
particl
form
spike
glycoprotein
envelop
e
membran
nucleocapsid
n
spike
type
transmembran
protein
form
two
subunit
involv
fusionentri
process
receptorbind
domain
rbd
respons
bind
cellular
receptor
fusion
peptid
fp
heptad
repeat
heptad
repeat
transmembran
domain
tm
cytoplasm
domain
peptid
cp
act
viral
fusion
entri
cell
three
segment
altogeth
form
sixhelix
bundl
fusion
core
disrupt
core
format
lead
viral
fusion
inhibit
therefor
prevent
infect
reason
gao
et
al
design
two
avp
base
sequenc
challeng
effect
pseudotyp
merscov
system
peptid
show
good
inhibitori
effect
show
activ
even
highest
concentr
anoth
assay
lu
et
al
also
design
peptid
base
region
merscov
among
test
perform
analyz
whether
peptid
interact
form
core
prove
sdspage
gel
suggest
interact
mimic
fusion
core
structur
vitro
academ
purpos
furthermor
cellcel
fusion
inhibit
assay
show
effici
inhibit
merscov
spread
syncytium
format
mechan
describ
author
could
interact
viral
domain
block
viral
fusion
core
format
addit
antivir
assay
perform
vero
cell
express
receptor
use
merscov
show
inhibit
viral
replic
dosedepend
manner
final
author
suggest
peptid
use
templat
design
analog
enhanc
activ
merscov
infect
possibl
use
clinic
patient
anoth
exampl
sun
et
al
inspir
fusion
core
protein
design
peptid
name
contain
three
copi
two
copi
besid
test
describ
peptid
structur
possibl
interact
anoth
mer
inspir
peptid
pseudotyp
inhibit
assay
cellcel
spread
assay
carri
result
show
inhibit
merspseudoviru
syncytia
format
final
author
suggest
peptid
may
prevent
interact
region
consequ
block
format
fusion
core
recent
group
design
peptid
region
test
proteinmedi
cellcel
fusion
pseudotyp
live
peptid
name
show
inhibit
cellcel
spread
inhibit
pseudoviru
infect
much
effect
besid
vivo
assay
show
could
retain
antivir
activ
upper
lower
respiratori
tract
administ
intranas
end
author
suggest
could
becom
antivir
drug
use
along
differ
antivir
molecul
differ
mechan
action
possibl
exert
synergist
activ
sinc
major
viral
infect
still
avail
treatment
due
emergencereemerg
viru
strain
chanc
viral
pandem
pose
real
threat
worldwid
popul
still
real
risk
highli
global
world
infect
individu
spread
diseas
much
faster
centuri
ago
exampl
ebola
viru
outbreak
spread
west
africa
endem
place
europ
unit
state
infect
health
care
agent
rise
diseas
led
world
health
organ
consid
public
health
event
intern
concern
therefor
novel
antivir
molecul
clinic
treatment
indispens
current
approach
prove
insuffici
case
nucleosid
analog
consid
satisfactori
past
first
gener
show
mani
side
effect
later
gener
struggl
viral
resist
indic
begin
review
mani
altern
propos
nowaday
antivir
peptid
among
summar
tabl
howev
even
sever
peptid
describ
antivir
molecul
actual
reach
clinic
trial
phase
despit
molecul
advantag
potenti
problem
still
need
address
first
product
cost
high
due
current
solidphas
techniqu
requir
coupl
reagent
resin
case
protect
amino
acid
process
becom
quit
challeng
depend
peptid
composit
instanc
presenc
disulfid
bridg
repetit
singl
amino
acid
residu
cost
reduct
could
achiev
rethink
synthesi
purif
method
like
use
recombin
peptid
express
second
short
halflif
poor
oral
absorpt
common
challeng
sinc
peptid
highli
suscept
degrad
proteas
peptidas
issu
could
solv
use
denantiom
allow
increas
human
filtrat
stabil
decreas
substrat
recognit
bind
affin
proteolyt
enzym
posttransl
modif
amid
acetyl
also
improv
peptid
stabil
even
addit
fatti
acid
chain
improv
membran
permeabl
final
challeng
deliveri
system
thu
depend
viral
target
viral
envelop
intracellular
replic
step
drug
administr
via
oral
parenter
solut
may
conjug
nanocarri
antibodi
carbohydr
lipid
develop
techniqu
produc
improv
pharmacodynam
pharmacokinet
avp
problem
overcom
one
day
sinc
interest
peptidebas
drug
rise
largescal
product
screen
speed
drug
discoveri
phase
expect
antivir
peptid
enter
phase
clinic
trial
even
recent
discov
virus
littl
inform
current
method
antivir
peptid
design
seem
work
drug
descript
also
help
understand
viral
structur
addit
author
suggest
use
peptidebas
drug
adjuv
combin
therapi
antivir
differ
mechan
action
thu
diminish
drug
resist
establish
produc
fewer
side
effect
final
descript
new
antivir
drug
supplement
exist
therapi
provid
altern
treat
viral
diseas
caus
seriou
pandem
reduc
mortalitymorbid
associ
